Jeremiah Sundararaj Stanleyraj

Dr. Jeremiah Sundararaj Stanleyraj

orcid
Lets solve the bigger mystery with one small step at a time

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in JAMA
Verified
Journal Article
Open access
PDF file
NSNandini Sethuraman
Nandini Sethuraman
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
ARAkihide Ryo
Akihide Ryo
This Viewpoint discusses the 2 most common categories of testing to diagnose SARS-CoV-2—real-time PCR to identify viral RNA and serological diagnosis of IgG and

1 November 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
KMKei Miyakawa
Kei Miyakawa
TMTakeshi Morita
Takeshi Morita
YYYutaro Yamaoka
Yutaro Yamaoka
ARAkihide Ryo
Akihide Ryo

1 January 2013 in Tropical Parasitology
Verified
Journal Article
Open access
PDF file
SPSubhash Chandra Parija
Subhash Chandra Parija
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
The unicellular protist Blastocystis has long been an unsolved puzzle for taxonomists, microbiologists and clinicians. Over the years, the organism has been bounced on and off the different branches of the tree of life due the possession of unique phenotypic characters intermediary to different organisms. The organism is polymorphic with only few of forms such as vacuolar, granular, amoeboid, and the cyst form being commonly known. However it could exist in other forms much more frequently than the widely known forms which could be missed by the unaware observer. Certain older concepts in the life cycle of Blastocystis although has been proven wrong are still being followed in various textbooks and other trustworthy internet sources. The causal role of Blastocystis in human disease has long been a subject of controversy. It is widely believed that certain subtypes of the organism are virulent. But this is not so as other factors are also involved in the clinical outcome of the infection. In these contexts, this review intends to shed light on the past misconceptions and the recent findings on the taxonomy, biology and the virulence of this organism.

19 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYayoi Kimura
Yayoi Kimura
YNYusuke Nakai
Yusuke Nakai
JSJihye Shin
Jihye Shin
MHMiyui Hara
Miyui Hara
YTYuriko Takeda
Yuriko Takeda
ARAkihide Ryo
Akihide Ryo
The COVID-19 pandemic is an unprecedented threat to humanity that has provoked global health concerns. Since the etiopathogenesis of this illness is not fully characterized, the prognostic factors enabling treatment decisions have not been well documented. Accurately predicting the progression of the disease would aid in appropriate patient categorization and thus help determine the best treatment option. Here, we have introduced a proteomic approach utilizing data-independent acquisition mass spectrometry (DIA-MS) to identify the serum proteins that are closely associated with COVID-19 prognosis. Twenty-seven proteins were differentially expressed between severely ill COVID-19 patients with an adverse or favorable prognosis. Ingenuity Pathway Analysis revealed that 15 of the 27 proteins might be regulated by cytokine signaling relevant to interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF), and their differential expression was implicated in the systemic inflammatory response and in cardiovascular disorders. We further evaluated practical predictors of the clinical prognosis of severe COVID-19 patients. Subsequent ELISA assays revealed that CHI3L1 and IGFALS may serve as highly sensitive prognostic markers. Our findings can help formulate a diagnostic approach for accurately identifying COVID-19 patients with severe disease and for providing appropriate treatment based on their predicted prognosis.

1 June 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
YYYutaro Yamaoka
Yutaro Yamaoka
KMKei Miyakawa
Kei Miyakawa
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
RFRikako Funabashi
Rikako Funabashi
KOKoji Okudela
Koji Okudela
ARAkihide Ryo
Akihide Ryo
The ongoing COVID-19 pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAb) that exclusively react with SARS-CoV-2 and exhibit no cross-reactivity with other human coronaviruses including SARS-CoV. Molecular modeling suggest that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 NP mAbs using ELISA, and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Due to their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.

23 May 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YYYutaro Yamaoka
Yutaro Yamaoka
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
KMKei Miyakawa
Kei Miyakawa
RSRyo Saji
Ryo Saji
MNMototsugu Nishii
Mototsugu Nishii
ARAkihide Ryo
Akihide Ryo
Yutaro Yamaoka, Sundararaj S Jeremiah, Kei Miyakawa, Ryo Saji, Mototsugu Nishii, Ichiro Takeuchi, Akihide Ryo; Whole nucleocapsid protein of SARS-CoV-2 may cau